| Code | CSB-RA023984MB18HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ZG-033, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells, NK cells, and other immune cell populations. Upon binding its ligand 4-1BBL, TNFRSF9 delivers critical signals that enhance T cell proliferation, survival, and cytotoxic function while promoting memory T cell formation. This receptor plays a pivotal role in regulating immune responses and has significant implications in cancer immunotherapy, autoimmune diseases, and viral infections.
ZG-033 serves as the reference antibody for this biosimilar product, representing an important tool for investigating TNFRSF9-mediated immune regulation. This antibody is valuable for researchers studying T cell activation mechanisms, tumor immunology, and the development of immune checkpoint-based therapeutics. It supports investigations into costimulatory signaling pathways and the therapeutic potential of targeting TNFRSF9 in various disease contexts, including solid tumors and hematological malignancies.
There are currently no reviews for this product.